The RNA‐binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma | Zendy

Panzeri Valentina | Zendy; Manni Isabella | Zendy; Capone Alessia | Zendy; Naro Chiara | Zendy; Sacconi Andrea | Zendy; Di Agostino Silvia | Zendy; Latouliere Luisa | Zendy; Montori Andrea | Zendy; Pilozzi Emanuela | Zendy; Piaggio Giulia | Zendy; Capurso Gabriele | Zendy; Sette Claudio | Zendy

Open Access

The RNA‐binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma

Author(s) -

Panzeri Valentina,

Manni Isabella,

Capone Alessia,

Naro Chiara,

Sacconi Andrea,

Di Agostino Silvia,

Latouliere Luisa,

Montori Andrea,

Pilozzi Emanuela,

Piaggio Giulia,

Capurso Gabriele,

Sette Claudio

Publication year - 2021

Publication title -

molecular oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.332

H-Index - 88

eISSN - 1878-0261

pISSN - 1574-7891

DOI - 10.1002/1878-0261.12847

Subject(s) - gemcitabine , pancreatic ductal adenocarcinoma , regulator , cancer research , adenocarcinoma , medicine , rna , pancreatic carcinoma , oncology , biology , pancreatic cancer , chemotherapy , cancer , gene , genetics

RNA dysregulation is a hallmark of most human cancers, including PDAC. We identify the RNA‐binding protein MEX3A as prognostic factor in PDAC. MEX3A regulates stability of transcripts for cell cycle proteins, such as CDK6, and promotes cell cycle progression and resistance to chemotherapeutic treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research